The Cigna Group (CI) Stock Price, News, Analysis

Technical Score (1D)

BUY

News Sentiment

BULLISH

Cigna (CI) is set to report its Q2 earnings later this month, a key event that could shape the stock’s near‑term trajectory. Analysts are projecting single‑digit earnings growth, suggesting a modest improvement over the prior quarter. The guidance points to stable revenue streams from its health‑insurance and managed‑care segments, indicating that the core business remains resilient. If the company delivers on the forecast, the market may interpret the results as confirmation of steady cash‑flow generation in a sector that is still navigating regulatory and cost‑pressure headwinds. Conversely, any shortfall could raise concerns about the sustainability of its pricing power and the impact of rising medical‑cost inflation. The earnings release will also likely include commentary on the performance of the health‑insurance and managed‑care arms, which are critical to understanding future revenue dynamics. Investors should watch for any revisions to the long‑term outlook, as an upward revision could signal confidence in the company’s ability to manage cost growth. Additionally, pay attention to any discussion of regulatory changes or payer mix shifts that could affect the company’s profitability. In the next 1–10 trading days, the market will be sensitive to how the actual earnings compare to the single‑digit growth expectation and whether the company signals any strategic adjustments.

CI|Company Info

Sector

Healthcare

Industry

Healthcare Plans

Exchange

NYQ

Country

United States

Website

thecignagroup.com

Symbol

Description

The Cigna Group is a U.S.-based healthcare company focused on delivering comprehensive health solutions. Its core business is divided into two primary segments: Evernorth Health Services and Cigna Healthcare. Evernorth provides a suite of coordinated health services, including pharmacy benefits management, care delivery solutions, and other related offerings to various clients. Cigna Healthcare offers a range of medical, dental, and behavioral health insurance products and services to individuals, seniors, and employer groups, both domestically and internationally. The company distributes its products through brokers, direct sales, and exchanges, catering to a diverse customer base. Originally founded in 1792 and headquartered in Connecticut, The Cigna Group has evolved to meet the complex needs of the healthcare market.

CI|Earnings Snapshot

Earnings Summary

CI, a U.S. healthcare conglomerate, delivers health solutions through its Evernorth Health Services and Cigna Healthcare segments, positioning it within the broader healthcare plans sector. In the most recent two quarters, revenue rose from $67.178 billion in Q2 2025 to $69.748 billion in Q3 2025, then dipped to $68.517 billion in Q1 2026, while EPS climbed from $7.20 to $7.83 before settling at $7.79; compared to the prior two quarters, revenue growth accelerated from $65.683 billion in Q4 2024 to $72.495 billion in Q4 2025, and EPS increased from $6.64 to $8.08, indicating a strong upward trend that has been sustained in most recent periods. Historically, CI has posted double‑digit revenue growth year‑over‑year, with a 10.4% jump to $72.495 billion in Q4 2025 and a 21.7% EPS rise to $8.08, and has consistently beat analyst estimates in five of the last six quarters, underscoring robust earnings momentum. Recent developments include Argus Research’s upgrade of CI’s target price to $315, the company’s $100 million investment in the Pharmacy Forward AI platform, and its removal from the Russell 1000 Growth and Russell 3000 Growth indices, all of which could influence short‑term liquidity and valuation dynamics. Investors should watch the Q2 2026 earnings release for guidance on revenue drivers, margin performance, and the progress of the Pharmacy Forward rollout, as well as any index rebalancing activity that may affect passive flows today.

Read full report

EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$7.60	-	-
Q1'26	$7.61	$7.79	+2.4%
Q4'25	$7.50	$8.08	+7.8%
Q3'25	$7.64	$7.83	+2.5%
Q2'25	$7.15	$7.20	+0.6%
Q1'25	$6.35	$6.74	+6.2%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$72.5B	-	-
Q1'26	$66.2B	$68.5B	+3.5%
Q4'25	$66.4B	$72.5B	+9.2%
Q3'25	-	$69.7B	-
Q2'25	-	$67.2B	-
Q1'25	-	$65.5B	-

Full Earnings BreakdownEstimates, actuals, guidance, and historical context

→

Market Data

CI Stock Snapshot

CI is currently trading at $291.50, giving The Cigna Group a market cap of 77.63B and a P/E ratio of 12.3. Today's range spans $289.31–$295.00, with shares opening at $293.57 and moving down $1.92 (0.7%) from the prior close. DailyIQ's technical score sits at 95/100 (BUY) with a news sentiment reading of 68/100.

Over the past year CI has traded between $239.51 and $315.47 - the current price is +21.7% off the 52-week low and -7.6% from the high. 35 analysts cover the stock with a Buy consensus and a mean 12-month target of $340.92 (range $290.00–$400.00), implying upside of +17.0%.

CI scores 95/100 (BUY) and is at $291.50 - in the upper portion of its 52-week range within its $239.51–$315.47 annual range. Sentiment at 68/100 is bullish. At 77.63B in Healthcare market cap (P/E: 12.3), this large-cap name benefits from a dynamic that mega-caps don't have: the potential for multiple expansion. When a name at this size with bullish momentum catches the attention of large allocators, the re-rating can be rapid and meaningful.

Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (95/100) and news sentiment (68/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $291.50 (in the upper portion of its 52-week range), CI's position within the $239.51–$315.47 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.

News Sentiment Analysis

Sentiment gathered from recent headlines

68/100

Strong NegativeNeutralStrong Positive

MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

Cigna (CI) will report Q2 results later this month. Analysts anticipate a single‑digit earnings growth, suggesting modest improvement over the prior quarter. The guidance indicates stable revenue streams from its health‑insurance and managed‑care segments. Investors should watch the earnings release for actual growth figures and any updates to long‑term outlook.

What did this article say?

Bernstein has increased its price target for CI to $381 from $371, citing a stronger earnings outlook and improved margin assumptions. The upgrade reflects confidence in CI’s growth prospects within its healthcare services portfolio. Traders should monitor CI’s upcoming earnings release and any new guidance that could validate the new target.

What did this article say?

Bernstein has increased its price target for Cigna (CI) to $381 from $371, reflecting a more bullish outlook. The brokerage maintains an overweight rating and notes an average analyst target of $340.65, indicating growing confidence in the insurer’s prospects. The upgrade suggests expectations of stronger earnings and improved market positioning. Traders should watch for CI’s upcoming earnings report and any shifts in regulatory policy that could influence the health‑insurance sector.

What did this article say?

Bernstein analyst Lance Wilkes has upgraded Cigna Group (CI) to an Outperform rating and raised its price target from $371 to $381. The upgrade signals a bullish view on CI’s earnings prospects and market positioning. The new target reflects confidence in CI’s ability to navigate the competitive health‑insurance landscape. Investors should monitor CI’s upcoming earnings release and any regulatory changes that could impact the sector.

What did this article say?

Argus Research has raised its target price for CI to $315, reflecting a more optimistic view of the company's growth prospects. The upgrade signals confidence in CI's ability to generate higher earnings and potentially improve its valuation multiples. Traders should monitor upcoming earnings releases and any guidance updates that could confirm or challenge this bullish outlook.

What did this article say?

Cigna Group (CI) will publish its second‑quarter 2026 financial results on Thursday, July 30, 2026, and will hold a conference call the same day. The announcement provides the date and time of the release and the call, but no guidance or performance details are disclosed yet. Investors should prepare to review the earnings report and listen to the call for insights into revenue drivers, margin performance, and any strategic updates.

What did this article say?

The Cigna Group (CI) has been dropped from the Russell 1000 Growth and Russell 3000 Growth indices, potentially altering its exposure to passive investment strategies. This change may lead to rebalancing by index funds, creating short‑term selling pressure and affecting liquidity. While the removal does not indicate a shift in Cigna’s business operations, it could influence the cost of capital and investor perception. Traders should watch for fund flow adjustments and changes in passive holdings.

What did this article say?

Cigna Group’s shares have delivered a 34.3% return over five years, yet the stock fell 8% in the past year. Current valuation metrics still flag the shares as cheap, suggesting a potential upside if the price reflects the underlying earnings strength. The mix of long‑term performance and recent price weakness raises the question of whether the current $287.77 price level truly captures the business’s value.

What did this article say?

Cigna Group (CI) has committed $100 million to Pharmacy Forward, an AI‑driven pharmacy platform, marking a significant push into digital pharmacy services. The investment is intended to streamline prescription fulfillment, reduce costs, and leverage data analytics for member care. While the bet could enhance CI’s competitive positioning, integration challenges and the need for regulatory approvals pose potential risks. Traders should assess how this initiative may influence CI’s earnings guidance and market perception in the coming quarters.

What did this article say?

Evernorth, the health services arm of Cigna (CI), launched Pharmacy Forward, an AI-powered program aimed at streamlining specialty pharmacy services. The initiative targets patients with chronic and complex conditions, integrating with Accredo Specialty Pharmacy and leveraging condition‑specific Therapeutic Resource Centers. By automating prescription processing and enhancing patient support, the program seeks to reduce turnaround times and improve adherence. Traders should monitor the rollout pace, patient uptake metrics, and any impact on Cigna’s specialty pharmacy revenue mix.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

CI·The Cigna Group

EPS

Revenue

CI Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Discover More

News Sentiment Analysis

Recent News Coverage

Discover More